Shares of Celgene, a biotech blue-chip stock that generates most of its revenue from the development of oncology, inflammation, and immunology drugs, dipped 11% in November, based on data from S&P ...
In a sudden management revamp, Celgene President and COO Scott Smith will leave his post at the biotech company, effective immediately. Celgene has recently suffered from a series of major setbacks ...
Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of ...
Flatiron Health, a New York City-based oncology technology company, has expanded its relationships with biotechnology company Celgene Corp. and biopharmaceutical company Amgen. Here are three things ...
Celgene’s shares have dropped nearly 30 percent since October, due to slow sales of its psoriasis drug Otezla, an upcoming patent cliff for its multiple myeloma drug Revlimid, and the failure of an ...
(NEW YORK) — Bristol-Myers Squibb announced on Thursday it is purchasing fellow drugmaker Celgene in a cash and stock deal valued at approximately $74 billion. Per the terms of the agreement, Celgene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results